| Name | Title | Contact Details |
|---|
Elanco Animal Health Incorporated is a prominent American pharmaceutical company focused on developing, manufacturing, and marketing medicines and vaccinations for pets and livestock. Established in 1954 as a division of Eli Lilly and Company, Elanco became an independent entity in 2018 and has since grown to be one of the largest independent animal health companies worldwide. The acquisition of Bayer Animal Health in 2020 significantly expanded its size and global reach. Elanco offers a wide range of products aimed at enhancing animal health and productivity. This includes pharmaceuticals and vaccines for livestock and companion animals, nutritional solutions to improve feed efficiency, and data analytics through its Elanco Knowledge Solutions division. The company serves a diverse customer base, including farmers, veterinarians, pet owners, and agricultural stakeholders, all dedicated to improving animal health and food quality. Elancos mission emphasizes the importance of food and companionship in enriching life, reflecting its commitment to animal welfare and innovation in the animal health sector.
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology`s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.
Opexa Therapeutics is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck.
Medusa Medical Technologies Inc is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.